In case you missed it, The Kaiser Permanente Washington Health Research Institute (KPWHRI) has given the first-ever injection of an investigational vaccine for the 2019 novel coronavirus, SARS-CoV-2, to 4 volunteers participating in a phase I federally sponsored clinical trial.
To this date, no other trial has been launched in people of any vaccine for this virus, which causes COVID-19. The KPWHRI trial in Seattle began recruiting participants on March 3.
“We are proud that the National Institute of Allergy and Infectious Diseases (NIAID) selected us to conduct this innovative trial,” said Lisa Jackson, MD, MPH, senior investigator at KPWHRI. “We’re well prepared and focused on helping to address this evolving health situation.” Dr. Jackson is the lead researcher for the study, funded by the U.S. National Institutes of Health.
“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said NIAID Director Anthony S. Fauci, M.D. in a NIAID news release. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”
Kaiser Permanente Washington Health Research Institute (SOURCE)
Kaiser Permanente Washington Health Research Institute
SHOP ON ATP STORE